Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maxygen granted approval for Factor VIIa trial in UK
Maxy-VII is the company’s next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of 2008. Russell Howard,
Maxy-VII is the company’s next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of 2008. Russell Howard,
Under the agreement, 3M will provide its patented toll-like receptor (TLR) agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties. 3M’s patented TLR immune response
MCR and AMBI are engaged in a specialty pharmaceutical business focusing on the development, marketing and distribution of branded and generic pharmaceutical products targeted primarily to the cough
Mr Henley joins Medicure from a private investment and management company where he held the position of vice president of finance. Prior to that Mr Henley’s was vice-president
Robert Kluge, corporate senior vice president of Varian, said: “This contract marks the latest chapter in our 30-year relationship with Toshiba Medical Systems. We have complementary design engineering
Of the first six evaluable patients in this Phase II trial one patient has had a confirmed objective response, as measured by Recist criteria. As part of the
The license provides Novartis with access to BioWa’s Potelligent technology platform to research, develop, manufacture, and commercialize antibody-dependent cellular cytotoxicity (ADCC)-enhanced antibodies for an undisclosed number of targets.
Under the terms of the settlement agreement, the litigation, which was pending before the US District Court of California, has now been fully resolved and dismissed. The settlement
The trial is for Aegera’s AEG35156, a targeted therapy for blood cancer patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. The clinical trials will take
The most advanced drug in the portfolio is expected to enter a Phase II clinical study later this year. The Phase II candidate and all other drugs in